14 November 2025
14 November 2025
The two drugmakers swiftly denied any affiliation with Mangoceuticals, who claimed it had partnered with them.
Along with the layoffs, the reshuffle includes prioritisation of pipeline assets with the “highest probability of success.”
Komzifti now becomes the first once-daily targeted therapy for r/r AML, though it will have to fight Syndax’s Revuforj for market share.
The approval aligns with recent regulatory decisions in countries including China and the US.
The OmniTAC platform enables unbiased screening of effector proteins that can modulate disease-relevant targets.
Aliada will receive upfront, sales-based payments, while Chiesi funds all development and commercialisation activities.
The research expands upon the investigator-initiated Phase II Nobel clinical study led by Dr Manabu Muto of Kyoto University.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
